
Pfizer Abrysvo gets European Commission nod for RSV Lower Respiratory Tract Disease in adults aged 18-59 years
New York: Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication …